Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Mechanisms of Insulin Resistance in Humans
This study is currently recruiting participants.
Verified by Department of Veterans Affairs, October 2008
Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00330967
  Purpose

The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery. which would cause minimal or no systemic hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during the systemic lipid infusion, and (2) determine the inflammatory response and insulin resistance in skeletal muscle during an infusion of lipid into the femoral artery as described above after NP-KB inhibition by high dose salicylate treatment in humans.


Condition Intervention
Inflammation
Insulin Resistance
Drug: 20% Intralipid
Drug: Salicylate

Drug Information available for: Insulin Dextrose Lipids
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Mechanisms of Insulin Resistance in Humans

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • degree of insulin resistance and inflammation [ Time Frame: immediate ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Blood samples, muscle biopsies


Estimated Enrollment: 32
Study Start Date: April 2006
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
healthy subjects
Drug: 20% Intralipid
lipid infusion
2
healthy subjects different from group 1
Drug: 20% Intralipid
lipid infusion
Drug: Salicylate
treatment with anti-inflammatory agent

Detailed Description:

Insulin resistance in skeletal muscle is a characteristic abnormality in obesity and the metabolic syndrome and a major factor responsible for the development of type 2 diabetes. Although the mechanisms responsible for muscle insulin resistance are largely unclear, lipid oversupply is an important factor. Among numerous potential mechanisms whereby lipid oversupply may cause muscle insulin resistance, current evidence points towards inflammation as being critical. Recent studies in animals, however, indicate that the inflammatory response in skeletal muscles may require the presence of circulating pro-inflammatory factors suggesting that the inflammation induced insulin resistance in skeletal muscles may be a secondary event. More specifically, activation of Nuclear Factor-Kappa B(NF-kB), and inflammatory master switch that drives the production of numerous pro-inflammatory cytokines in fat and liver, has been implicated in causing insulin resistance in skeletal muscles by increasing circulating pro-inflammatory cytokines. In contrast, animal studies have found that activation of NP-KB directly in skeletal muscles has no or little effect on its insulin sensitivity but does produce other abnormalities such as increased proteasome activity. The study shall therefore be undertaken to determine to what extent lipid-induced inflammation and insulin resistance in skeletal muscles requires the presence of circulating proinflammatory factors in humans.

  Eligibility

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

healthy subjects

Criteria

Inclusion Criteria:

- two groups of 16 healthy subjects

Exclusion Criteria:

  • diabetes or impaired glucose tolerance
  • peripheral vascular disease
  • pulmonary disease
  • clinically significant hepatic or renal disease
  • triglycerides >200mg/dl
  • anemia
  • abnormal PT, PTT or INR
  • pregnancy or lactation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00330967

Contacts
Contact: Donald L Gates, PhD (602) 277-5551 ext 6918 donald.gates2@va.gov

Locations
United States, Arizona
Carl T. Hayden VA Medical Center Recruiting
Phoenix, Arizona, United States, 85012
Contact: Donald L Gates, PhD     602-277-5551 ext 6918     donald.gates2@va.gov    
Principal Investigator: Christian Meyer, MD            
Sponsors and Collaborators
Investigators
Principal Investigator: Christian Meyer, MD Carl T. Hayden VA Medical Center
  More Information

Responsible Party: Department of Veterans Affairs ( Meyer, Christian - Principal Investigator )
Study ID Numbers: ENDA-029-05F
Study First Received: May 26, 2006
Last Updated: October 30, 2008
ClinicalTrials.gov Identifier: NCT00330967  
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Fat Emulsions, Intravenous
Free Fatty Acids
Glucose Clamp Technique
Inflammation
Insulin Resistance
Muscle, Skeletal
NF-Kappa B
Salicylates

Study placed in the following topic categories:
Hyperinsulinism
Metabolic Diseases
Salicylates
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Insulin
Inflammation

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Pharmacologic Actions
Pathologic Processes
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009